Table 1 Patient characteristics of the entire cohort
SABR (n = 54) | CFRT (n = 86) | |||
|---|---|---|---|---|
Variable | No. of patients (%) | No. of patients (%) | p-value | SMD |
Time of treatment | 0.789 | 0.047 | ||
Before December 31, 2011 | 27 (50.0) | 45 (52.3) | ||
After December 31, 2011 | 27 (50.0) | 41 (47.7) | ||
Age, year | 0.494 | 0.243 | ||
Mean (SD)*, range | 61.0 (12.9), 32–84 | 59.6 (11.2), 34–90 | ||
≤ 60 | 23 (42.6) | 47 (54.7) | ||
> 60 | 31 (57.4) | 39 (45.3) | ||
Sex | 0.766 | 0.052 | ||
Male | 42 (77.8) | 65 (75.6) | ||
Female | 12 (22.2) | 21 (24.4) | ||
Liver disease | 0.281 | 0.086 | ||
HBV | 29 (53.7) | 56 (65.1) | ||
HCV | 17 (31.5) | 16 (18.6) | ||
HBV and HCV | 1 (1.9) | 4 (4.7) | ||
Non-virus | 7 (13.0) | 10 (11.6) | ||
ECOG | 0.887 | 0.025 | ||
0–1 | 46 (85.2) | 74 (86.0) | ||
2 | 8 (14.8) | 12 (14.0) | ||
Extrahepatic metastasis | 0.993 | 0.001 | ||
Yes | 5 (9.3) | 8 (9.3) | ||
No | 49 (90.7) | 78 (90.7) | ||
AFP, ng/ml | 0.960 | 0.009 | ||
≤200 | 23 (42.6) | 37 (43.0) | ||
> 200 | 31 (57.4) | 49 (57.0) | ||
Child-Pugh class | 0.086 | 0.303 | ||
A | 35 (64.8) | 43 (50.0) | ||
B | 19 (35.2) | 43 (50.0) | ||
Prior treatment | 0.047 | 0.350 | ||
Yes | 30 (55.6) | 33 (38.4) | ||
No | 24 (44.4) | 53 (61.6) | ||
No. of tumor | 0.894 | 0.023 | ||
Multiple | 37 (68.5) | 58 (67.4) | ||
Single | 17 (31.5) | 28 (32.6) | ||
Tumor size, cm | 0.088 | 0.298 | ||
≤8 | 28 (51.9) | 32 (37.2) | ||
> 8 | 26 (48.1) | 54 (62.8) | ||
PVI location | 0.128 | 0.267 | ||
Vp4 | 23 (42.6) | 48 (55.8) | ||
Vp3 | 31 (57.4) | 38 (44.2) | ||
Sorafenib | 0.825 | 0.038 | ||
Yes | 23 (42.6) | 35 (40.7) | ||
No | 31 (57.4) | 51 (59.3) | ||
BED, Gy | < 0.001 | 1.075 | ||
< 65 | 14 (25.9) | 63 (73.3) | ||
≥ 65 | 40 (74.1) | 23 (26.7) |